Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

ABSTRACT: This phase II trial studies how well danvatirsen and durvalumab work in treating patients with pancreatic cancer, non-small cell lung cancer and mismatch repair deficient colorectal cancer that has spread to other places in the body and does not respond to treatment. Danvatirsen may be used to block the production of proteins needed for tumor cell growth. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving danvatirsen and durvalumab may work better at treating pancreatic cancer, non-small cell lung cancer and mismatch repair deficient colorectal cancer.

DISEASE(S): Stage Iva Colorectal Cancer Ajcc V8,Stage Iiic Lung Cancer Ajcc V8,Carcinoma,Mismatch Repair Deficiency,Lung Neoplasms,Stage Iiic Colorectal Cancer Ajcc V8,Stage Iiia Lung Cancer Ajcc V8,Stage Ivb Colorectal Cancer Ajcc V8,Stage Iii Pancreatic Cancer Ajcc V8,Colorectal Neoplasms,Carcinoma, Non-small-cell Lung,Stage Iv Pancreatic Cancer Ajcc V8,Pancreatic Neoplasms,Stage Iiib Colorectal Cancer Ajcc V8,Stage Ivc Colorectal Cancer Ajcc V8,Stage Iii Lung Cancer Ajcc V8,Stage Iv Colorectal Cancer Ajcc V8,Stage Iiib Lung Cancer Ajcc V8,Advanced Colorectal Carcinoma,Lung Non-small Cell Carcinoma,Stage Iva Lung Cancer Ajcc V8,Stage Iiia Colorectal Cancer Ajcc V8,Stage Ivb Lung Cancer Ajcc V8,Stage Ii Pancreatic Cancer Ajcc V8,Advanced Lung Non-small Cell Carcinoma,Refractory Lung Carcinoma,Stage Iii Colorectal Cancer Ajcc V8,Stage Iv Lung Cancer Ajcc V8,Refractory Pancreatic Carcinoma,Refractory Colorectal Carcinoma

PROVIDER: 2231356 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR